<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Physiology and Pharmacology</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3AE51887-EFDC-4A10-8835-4B01439DF9C3"><gtr:id>3AE51887-EFDC-4A10-8835-4B01439DF9C3</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Bates</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CBBF15D1-E585-4BB2-B771-2C5389376BA5"><gtr:id>CBBF15D1-E585-4BB2-B771-2C5389376BA5</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Howard</gtr:otherNames><gtr:surname>Salmon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DF566A03-F8DF-4AB9-AD23-307020545E6C"><gtr:id>DF566A03-F8DF-4AB9-AD23-307020545E6C</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Harper</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002073"><gtr:id>EB89F329-DE07-45E6-B652-6653E1B137BB</gtr:id><gtr:title>Manipulation of Vascular Endothelial Growth Factor isoform-repertoire as a potential therapy in chronic kidney disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1002073</gtr:grantReference><gtr:abstractText>End stage kidney failure is becoming increasingly common across the developed world, in the UK averaging a 4% increase per year. The 47,515 UK patients requiring renal replacement therapy (dialysis or transplantation) experience more frequent medical complications and reduced life expectancy compared to the general population and require the commitment of significant financial resources, representing 3% of the entire NHS budget consumed by 0.08% of the population. Many kidney diseases stem from injury to the kidney filters or glomeruli. In health these filtering units are very permeable to water and small molecules (promoting the production of urine) but have a low permeability to proteins (which are important molecules to conserve). Thus the filters have a selective permeability to different substances. In many kidney diseases this selective permeability is lost and protein leaks into the urine (proteinuria). Furthermore, for reasons that are not clear, the presence of protein in the urine has also recently been identified as a very strong predictor of cardiovascular disease (stokes, heart attacks etc). The glomeruli contains cells (podocytes) that produce molecules such as Vascular Endothelial Growth Factor (VEGF) that regulate glomerular function. The VEGF gene codes for different forms of VEGF that often have opposing actions. We intend to study the effects of two forms of VEGF - VEGF165 and VEGF165b in models of disease in which expression of these molecules may be controlled. We will also investigate how molecules that control the balance of the types of VEGF may be helpful in controlling filter permeability. This study may therefore allow the development of novel strategies to maintain normal or re-establish normal selective permeability. This may therefore have profound implications not only for kidney patients but also those at risk of cardiovascular disease producing significant financial benefits for health service providers.</gtr:abstractText><gtr:technicalSummary>Deranged glomerular permeability and subsequent proteinuria are cardinal features of glomerular disease which is identified(2008 Renal Registry report) as the primary cause of End Stage Renal Failure(ESRF) in 56.5% of cases, including those with presumed glomerular disease without histological characterisation and those with diabetic glomerular damage (24%). In turn ESRF is associated with increased morbidity (Na/water retention, hypertension, dyslipidaemia, vascular disease) and reduced longevity (5 year survival on dialysis = 46.3% [equivalent Grade II carcinoma stomach] and 25.1% if diabetic). Furthermore, the presence of protein in the urine is a strong predictor of cardiovascular risk in the general population, even in those individuals who have high normo-albuminuric levels. 
 This project will attempt to define the molecular basis for deranged glomerular permeability using a unique combination of transgenic animals, functional assays of intact glomerular filtration barriers (GFB), 3D-Electronic Microscopic reconstruction united with expertise in VEGF, a constitutively expressed podocyte growth factor which has multiple isoforms with contrasting properties. 
 The two permeability parameters: hydraulic conductivity (convective permeability to water) and reflection co-efficient (macromolecular selectivity) will be investigated in glomeruli from our recently described unique transgenic animal line that over-expresses the anti-permeability and glomerular cyto-protective VEGF isoform VEGF165b when crossed with i) animals known to over-express pro-permeability VEGF isoforms; ii) transgenic animals in which chronic podocyte injury occurs spontaneously or can be induced in a dose dependant way. In addition, to relate structure to function, the glomerular filtration barrier region (including sub-podocyte and interpodocyte spaces recently identified in this laboratory) from the same glomeruli from which the physiological parameters have been defined, will be reconstructed in three dimensions at the ultrastructural level. 
 The ability of agents which control VEGF isoform balance at the splicing level to influence functional permeability phenotype will also be investigated in cannulated isolated glomeruli, and human archive tissue will be examined to confirm that deranged VEGF isoform balance is a feature of human glomerular disease. 
 The combination of these highly specialised resources and skills is unrivalled worldwide and will provide a unique opportunity to elucidate how VEGF-isoform balance influences glomerular permeability. This project may allow the development of novel strategies to maintain or re-establish normal glomerular permeability. Our findings may therefore have profound implications, not only for renal patients and those at risk of cardiovascular disease but also for wider clinical fields e.g cancer (as deranged VEGF splicing is also a feature of malignancy).</gtr:technicalSummary><gtr:fund><gtr:end>2014-10-09</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-10</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>431133</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>408DBAF0-2F18-4647-A104-2855FDA88815</gtr:id><gtr:title>Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4995fb294220910a61b0946db62ed901"><gtr:id>4995fb294220910a61b0946db62ed901</gtr:id><gtr:otherNames>Oltean S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>Afbcvfd1Znf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2798BA4-B837-4A42-8B85-2A4B9DB30BCC</gtr:id><gtr:title>The role of VEGF-A165b in trophoblast survival.</gtr:title><gtr:parentPublicationTitle>BMC pregnancy and childbirth</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cf96ae9be26f1810b8abdca48a69924"><gtr:id>0cf96ae9be26f1810b8abdca48a69924</gtr:id><gtr:otherNames>Bills VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2393</gtr:issn><gtr:outcomeId>5453b27a25aa44.99704341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07EE2E24-5588-482A-8BF4-F5B10ACA2EB1</gtr:id><gtr:title>The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy.</gtr:title><gtr:parentPublicationTitle>Angiogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bfb230cdd97db612086868f3abfb62d"><gtr:id>1bfb230cdd97db612086868f3abfb62d</gtr:id><gtr:otherNames>Carter JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-6970</gtr:issn><gtr:outcomeId>5453b279a17465.61399274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6ACC50AA-E81F-48C5-ACB9-A33AB445956D</gtr:id><gtr:title>Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8779a1576b6dd1d616701d6dea8e4339"><gtr:id>8779a1576b6dd1d616701d6dea8e4339</gtr:id><gtr:otherNames>Hulse RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>5453b279f14213.81666258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8716A099-ED84-4DBD-AE90-A47BAD1B3A3E</gtr:id><gtr:title>SRPK1 inhibition and modulation of VEGF alternative splicing as a potential therapeutic strategy in prostate cancer</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1d72062760d6bc676f00fee841525a1"><gtr:id>a1d72062760d6bc676f00fee841525a1</gtr:id><gtr:otherNames>Athina MAVROU</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>5453b33d840319.80765110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACAB904B-68BD-49F4-9FAE-904E24C421E2</gtr:id><gtr:title>Novel mechanisms of resistance to vemurafenib in melanoma - V600E B-Raf reversion and switching VEGF-A splice isoform expression.</gtr:title><gtr:parentPublicationTitle>American journal of cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23697e55e02fdccdb74b54cae1dd7802"><gtr:id>23697e55e02fdccdb74b54cae1dd7802</gtr:id><gtr:otherNames>Beazley-Long N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2156-6976</gtr:issn><gtr:outcomeId>56e17fdb5cd634.17298350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BFA4BA2-422E-481C-AADE-355FF3671412</gtr:id><gtr:title>Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bec1957aed31e1c2fd5aedc13db614d2"><gtr:id>bec1957aed31e1c2fd5aedc13db614d2</gtr:id><gtr:otherNames>Hamdollah Zadeh MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>5453b279c9fbd6.17736415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1333AAF-EA18-4BB3-8BB0-760E5F441ECF</gtr:id><gtr:title>Detection of VEGF-A(xxx)b isoforms in human tissues.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c09613ef5f756f30f1f8cc349399f83"><gtr:id>8c09613ef5f756f30f1f8cc349399f83</gtr:id><gtr:otherNames>Bates DO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12517_27_23935865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B0F8688-62D0-407F-A33D-7C6D6C70D6F8</gtr:id><gtr:title>Resolution of the three dimensional structure of components of the glomerular filtration barrier.</gtr:title><gtr:parentPublicationTitle>BMC nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b392b06b40e18e403962722cb1300bab"><gtr:id>b392b06b40e18e403962722cb1300bab</gtr:id><gtr:otherNames>Arkill KP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2369</gtr:issn><gtr:outcomeId>5453b27a762035.80029393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1B9EE5F-11AE-4393-90A3-7936B54C1105</gtr:id><gtr:title>Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8779a1576b6dd1d616701d6dea8e4339"><gtr:id>8779a1576b6dd1d616701d6dea8e4339</gtr:id><gtr:otherNames>Hulse RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>56e17fdb2fd187.36157064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89C3E2A4-5E46-444F-8F30-964556F77FBF</gtr:id><gtr:title>Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios.</gtr:title><gtr:parentPublicationTitle>American journal of cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d41de7df9bae253e4f31995db81c234"><gtr:id>0d41de7df9bae253e4f31995db81c234</gtr:id><gtr:otherNames>Bunni J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2156-6976</gtr:issn><gtr:outcomeId>56dd7b7e759110.04071623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DA2A9B1-530B-43D5-94B5-DD4F44F56EC0</gtr:id><gtr:title>Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1966c872a8a04b1b9fe9d7229ec7e3fd"><gtr:id>1966c872a8a04b1b9fe9d7229ec7e3fd</gtr:id><gtr:otherNames>Mavrou A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>56e17fdbc3af53.96714244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C68C909-4487-45D8-8026-6E73F10CBD92</gtr:id><gtr:title>TNF-a-induced ICAM-1 expression and monocyte adhesion in human RPE cells is mediated in part through autocrine VEGF stimulation.</gtr:title><gtr:parentPublicationTitle>Molecular vision</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afe115853c6d6538f0719bbe84086b87"><gtr:id>afe115853c6d6538f0719bbe84086b87</gtr:id><gtr:otherNames>Thichanpiang P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1090-0535</gtr:issn><gtr:outcomeId>5453b27a4e8213.19471780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55D095C7-1250-45F3-833A-FFFB26BEDE70</gtr:id><gtr:title>VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Renal physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4995fb294220910a61b0946db62ed901"><gtr:id>4995fb294220910a61b0946db62ed901</gtr:id><gtr:otherNames>Oltean S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1522-1466</gtr:issn><gtr:outcomeId>L7wyWRKV2kv</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002073</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>